RxDoctor Payments Data

Michael Epstein, MD

Hematology & Oncology · Fort Wayne, INNPI 1437151347

Payments from drug & device makers

$30,592in general payments, 2019–2025

Across 741 payments — averaging $41.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$9K
  • Pharmacosmos Therapeutics Inc.$3K
  • Johnson & Johnson$2K
  • Novartis$2K
  • Merck$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$1,9509%
  • Speaking & faculty fees$2,0509%
  • Travel & lodging$1,2095%
  • Food & beverage$15,41168%
  • Education$1,0865%
  • Other$8814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen34$8,878
Pharmacosmos Therapeutics Inc.6$2,659
Johnson & Johnson(2 entities)71$2,051
Novartis57$1,508
Merck79$1,108
E.r. Squibb & Sons, L.L.C.37$1,087
AstraZeneca(2 entities)42$1,072
Caris MPI, Inc.4$1,053
Pfizer48$891
Genentech USA, Inc.30$842
Daiichi Sankyo Inc.13$659
Gilead(2 entities)21$631
Sanofi16$542
Takeda Pharmaceuticals U.S.A., Inc.15$514
AVEO Pharmaceuticals, Inc.9$507
Pharmacyclics LLC, An Abbvie Company19$467
Beigene, Ltd.1$450
AbbVie20$432
Exelixis Inc.11$431
Bristol Myers Squibb23$393
Athenex Pharmaceutical Division, LLC2$350
GSK15$326
Regeneron Healthcare Solutions, Inc.10$302
Eisai Inc.14$264
Jazz Pharmaceuticals Inc.8$255
Array Biopharma Inc15$204
Incyte Corporation10$194
Rigel Pharmaceuticals, Inc.7$189
Sanofi-aventis U.S. LLC3$160
Seagen Inc.9$143
Dova Pharmaceuticals2$135
Sanofi US Services Inc.1$129
Verastem, Inc.1$120
Bayer6$114
GE HealthCare5$104
Comsort, Inc1$100
Lilly USA, LLC5$95
Sobi, Inc5$88
Beigene USA, Inc.6$86
QOL Medical, LLC3$75
EMD Serono, Inc.4$73
Boehringer Ingelheim4$64
Adaptive Biotechnologies Corporation3$62
Pharmaessentia USA Corporation3$58
Morphosys, US Inc.4$57
Stemline Therapeutics Inc.3$51
Syndax Pharmaceuticals, Inc.2$46
Janssen Scientific Affairs, LLC3$45
CTI Biopharma Corp.3$45
Ipsen Biopharmaceuticals, Inc2$37
Taiho Oncology, Inc.2$34
Astellas Pharma US Inc2$33
Deciphera Pharmaceuticals Inc.2$33
Tersera Therapeutics LLC2$33
G1 Therapeutics, Inc.2$30
Foundation Medicine, Inc.1$27
ADC Therapeutics America, Inc.1$24
Puma Biotechnology, Inc.1$22
Epizyme, Inc.1$22
Geron Corporation1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,592 in reported general payments places this provider in the 60th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$2,260,896
Medicare patients
423
Services billed
141,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib37$548,811
RevlimidLenalidomide30$502,823
IdhifaEnasidenib Mesylate12$409,983
FotivdaTivozanib Hcl11$333,835
IbrancePalbociclib21$329,150
XtandiEnzalutamide23$320,697
CalquenceAcalabrutinib Maleate18$279,400
NinlaroIxazomib Citrate19$250,942
LynparzaOlaparib11$207,200
XareltoRivaroxaban74$78,980
EliquisApixaban36$34,230
Fentanyl11$2,166
Gabapentin132$1,929
Imatinib Mesylate19$1,804
Anastrozole133$1,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid, Idhifa$393$912,80642 claims
Beigene USA, Inc.Brukinsa$86$548,81137 claims
AstraZenecaCalquence, Lynparza$1,072$486,59929 claims
PfizerIbrance, Eliquis$891$363,38057 claims
Astellas Pharma US IncXtandi$33$320,69723 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$514$250,94219 claims
Johnson & JohnsonXarelto$2,051$78,98074 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 224 hematology & oncology providers in Indiana.

Other hematology & oncology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →